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Abstract
The availability of complete genomic sequences of Saccharomyces cerevisiae has catalyzed a cultural
change in the practice of yeast biology, providing opportunities to develop high throughput techniques
to define protein function, to define drug targets, and to discover and characterize drugs.
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For decades, yeast biology has been dually justified as an
effort to understand fully the cellular processes of a group
of single-celled eukaryotes and for its potential to lead to
advances in human health. Sequence-based trees of life
provide compelling evidence that plants, animals and fungi
- once considered three primary kingdoms in a five-
kingdom tree - are closely related branches within the
eukaryotic domain [1]. It is well known that homologs of
proteins first identified for key roles in yeast cell-cycle
control [2], secretion [3] and pro-hormone processing [4]
play similar roles in humans. Furthermore, similarities
between fungal, animal and plant cells have created chal-
lenges in developing fungal-directed antibiotics that are not
toxic to hosts. Although yeast biology has illuminated many
processes in yeast and human cells by homology, the yeast
cell has also become a laboratory of heterology. In the
1980s, heterologous use of yeast typically referred to
protein production [5]. In the 1990s, legions of researchers
were introduced to yeast two-hybrid systems to identify
binding partners of proteins expressed in yeast [6].
Although it is too early to predict the leading heterologous
use of yeast of the next decade, screens and selections to
identify small molecules that act on proteins expressed in
yeast hold tremendous promise [7]. The power of combina-
torial chemistry to screen huge numbers of drugs can now
be multiplied by the power of yeast genetics to assay genetic
variation. At a recent Camrbidge Healthtech Institute
meeting in Miami entitled ‘Exploiting Yeast Molecular
Biology for Therapeutics’ (January 20–21, 2000), some of
the latest homologous and heterologous uses of yeast
biology were presented, along with new methods for study-
ing yeast biology that became conceivable in the post-
genomic era.
Given a substrate, find the enzyme
Thousands of yeast genes and their corresponding products
were identified by classical genetic approaches that began
with identification of mutant phenotype and progressed
‘forward’ to the gene and product. Thousands of other genes
were discovered by ‘reverse’ genetic approaches, in which
mutants were obtained last. The original reverse genetics
experiments were fractionation-based; one purified a protein
of interest, sequenced it, and then cloned and disrupted the
corresponding gene (for example, see [8]). More recently,
reverse genetic approaches have been driven by identification
of homologous sequences (for example, see [9-11]). The
availability of complete genomic information has made possi-
ble a new type of reverse genetics not driven by sequence sim-
ilarity but rather based on a novel fractionation scheme.
For example, when Mark Martzen, Elizabeth Grayhack and
Eric Phizicky at the University of Rochester set out to iden-
tify an enzyme, they began in the classical manner by devel-
oping an assay to screen for activity. Rather than
fractionating a large, single yeast lysate to identify the
enzyme by biochemical means, these researchers used a set
of yeast strains carrying fusions of glutathione-S-transferase
(GST) to 6,080 open reading frames (ORFs) [12]. The GST
fusions, developed in the laboratory of Stanley Fields at the
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University of Washington [13], were grown in 64 pools, each
containing 95 ORF-GST fusions plus one control GST con-
struct. To identify the gene responsible for an enzyme activity
of interest, Martzen and colleagues first screened the 64 pools
to identify which one contained the activity. Because each
pool originated from constructs held in a 96 well plate, they
then screened the 8 rows and 12 columns from the identified
plate. The single point of intersection of pooled rows and
pooled columns defines the single ORF responsible for an
activity. The first publication from the Martzen group using
this technique described three enzymes identified in this way
[12], and the group’s biochemical genomics scoreboard now
includes a DNA-binding protein and numbers 12 additional
enzymes, several of which carry out RNA splicing reactions.
Given an enzyme, validate it as a drug target
In humans, elevated serum homocysteine concentration is
associated with vascular, skeletal and neurological disorders.
The most common genetic basis for clinical presentation of
severe hyperhomocysteinemia is cystathionine β-synthase
(CBS) deficiency, found in 1 child in about 300,000 [14].
Moreover, levels of homocysteine vary in populations and
there is strong epidemiological linkage between elevated total
homocysteine levels and vascular disease and stroke [15].
Whereas 50% of CBS-deficient patients respond to high doses
of vitamin B6, and vitamin B6 can also reduce total homocys-
teine in the majority of the human population, a specific drug
that could boost Cbs enzyme activity in CBS-deficients and in
those at risk for stroke might improve the quality of life for
many people. Warren Kruger of the Fox Chase Cancer Center
has developed a simple yeast-based assay to phenotype
human CBS genes and has validated mutant forms of Cbs as
targets that could be remedied by drugs. Wild-type human
CBS coding sequences complement the cysteine deficiency of
S. cerevisiae cys4 deletion mutants, and loss-of-function
alleles of human CBS fail to complement cys4 [16]. In the
course of cloning new CBS alleles, Kruger’s laboratory ampli-
fied a patient’s CBS genes and recovered a large number of
yeast transformants that were cys- and two that were CYS+.
The two CYS+ isolates contained PCR-induced intragenic
suppressor mutations of the patient’s loss-of-function allele.
Both mutations resulted in truncation of an inhibitory
carboxy-terminal domain. Nearly all CBS patients carry mis-
sense mutations and nearly all of these alleles are suppressed
by deletion of the carboxy-terminal domain [17]. At the
Miami meeting, Kruger presented data showing that a variety
of point mutations in the carboxy-terminus suppress the
hypomorphic phenotypes of CBS mutations and that
carboxy-terminal suppressors are not allele-specific. Thus,
chemical inactivation of the carboxy-terminal domain of Cbs
should be achievable and should boost the function of low-
activity enzymes. Furthermore, the combinatorial chemist
has a choice of primary screens: increase mutant Cbs enzyme
activity in vitro or generate prototrophy in a cys4 yeast strain
carrying mutant human CBS.
Given a target, find a drug
Kathleen Young of Wyeth-Ayerst Inc. spoke about her
group’s efforts to find ‘disinactivators’ of a human potassium
channel, Kv1.1/Kvβ1. Inactivation of such channels, medi-
ated by an interaction between the S4-S5 cytoplasmic linker
domain of the α subunit and the amino-terminal inactiva-
tion ball of the β subunit [18] might be associated with
seizures and hippocampal ischemia [19]. For this reason,
small molecules that block the association of specific α and β
subunits are considered to have therapeutic potential. As
demonstrated earlier with calcium channel fragments [7],
two-hybrid interactions can be constructed to produce
growth inhibition such that drugs that block the interaction
restore growth. The new screen for potassium channel disin-
activators involved more than 176,000 compounds and has
apparently identified a compound, WAY-349, with in vitro
efficacy and specificity for the Kv1.1/Kvβ1 channel.
Given a drug, find the target
Although protein-target-directed screening has become the
predominant way to identify small molecules today, the
majority of approved drugs were identified on the basis of
animal or cellular assays. In fact, most of the classical com-
pounds that owe their roots to botanicals and other natural
products were originally identified by human self-medication.
Thus, it should come as no surprise that a great many drugs
have modes of action that are not understood. John Phillips
and his colleagues at Rosetta Inpharmatics Inc. use two
genomic methods to clarify the mode of action of drugs. First,
they have developed a complete set of promoter fusions to the
green fluorescent protein of Aequoria victoria that allows
them to monitor the effect of a small molecule on the expres-
sion of each yeast gene [20]. Administration of a drug to yeast
strains transformed with the set of reporter constructs pro-
vides a fluorescent profile of the genes that become activated
or repressed in response to a drug. In the best cases, such as
that of erg11, the ergosterol-starved gene expression profile of
erg11 mutant cells is indistinguishable from that of cells
treated with the antifungal drug clotrimazole. Second, they
test the drug sensitivity [21] of a large and growing set of
strains that are heterozygous for individual open reading
frames [22,23]. Because each gene disruption strain carries
two unique 20 nucleotide ‘barcodes’, deletion mutants can be
maintained in a pool [22,23]. Upon drug administration, the
relative viability of each deletion strain can be assessed by
amplification of barcodes from the pooled strains using fluo-
rescently-labeled PCR primers and array hybridization to a
DNA chip containing the barcode oligonucleotide probes [21].
Particular deletion mutants that are more sensitive to a drug
than the majority of deletion mutants produce a less fluores-
cent signal upon drug administration and are identifiable by
losses of particular barcode signals. The most drug-sensitive
strains are those in which the gene products targeted by the
drugs have been rendered heterozygous [21]. This method is
complementary to the classical method of cloning the target
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by virtue of multicopy-plasmid-dependent resistance [24].
The advantage of the new method is that it is highly parallel.
New compounds can be profiled with ease, and can be used to
identify not only primary and secondary targets via sensitivity
[25] but, additionally, loss-of-function mutations that result
in drug-resistance.
Given a pathogenic fungus, find a drug target
Candida species are among the most common fungal
pathogens to humans. C. albicans, which is asexual and
diploid, is refractory to ‘forward’ or classical genetics though
C. glabrata is a haploid and, thus, conditionally essential
genes or genes essential for adhesion to human epithelial
cells can be identified by forward mutagenesis and screening.
Having developed methods for homologous and nonhomolo-
gous integrative transformation in C. glabrata [26], Brendan
Cormack (Johns Hopkins University) selected 96 40mer
oligonucleotide barcodes and integrated them into the dis-
rupted ura3 locus of a C. glabrata strain. Each of these bar-
coded strains was then subjected to random insertional
mutagenesis with the S. cerevisiae URA3 gene and 100 inde-
pendent URA+ integrants were frozen away for each barcoded
strain [27]. In each strain, the URA3 insertion is expected to
have affected a different gene. By picking one transformant
from each of the 96 barcoded transformations, Cormack was
able to assemble 100 pools each containing an independent
URA3 insertion in a uniquely identifiable strain.
Cormack has already described a screen in which 50 of the
pools, representing as many as 4,800 independent
C. glabrata mutants, were passaged through an adherence
assay on human cultured epithelial cells. By probing a DNA
‘macrochip’ (a nylon filter the size of a 96 well plate on which
the 96 bar-code oligonucleotides were spotted) with radioac-
tively labeled barcode PCR reactions from C. glabrata cells
that grew on human cells, Cormack identified 16 mutants
that failed to adhere. Of these, 14 contained insertions in the
same gene, named EPA1 for epithelial adhesin, a calcium-
dependent lectin with a consensus sequence for addition of a
glycosyl-phosphatidylinositol anchor [27]. Cormack also
presented data showing that pools of barcoded mutant
C. glabrata strains can be passaged through a mouse in the
primary mutant hunt: 96 mutants being screened per
animal. Cormack’s approach of barcoding the cells to be
mutagenized rather than linking the barcode to the mutants
makes his barcodes reusable and independent of specialized
array hybridization equipment.
Though the yeast genome has been complete for four years,
the majority of yeast gene functions are poorly characterized.
Many of the approaches presented in Miami have the poten-
tial to assign functions to significant portions of the yeast
proteome. As knowledge of yeast cell biology expands, one
can expect greater light to be reflected on all eukaryotes and
further cultivation of yeast for pharmacological applications.
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